All Pharma News
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
REUTERS
06 Apr 2024
Share Share
Daiichi Sankyo`s Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.

Daiichi Sankyo`s Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.
FDA
05 Apr 2024
Share Share
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy
BUSINESSWIRE
05 Apr 2024
Share Share
Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients

Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients
BUSINESSWIRE
03 Apr 2024
Share Share
AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer

AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer
INDIANPHARMAPOST
02 Apr 2024
Share Share
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe

CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
BUSINESSWIRE
22 Mar 2024
Share Share
Two Datopotamab Deruxtecan Applications Validated in EU for Patients with NSCLC

Two Datopotamab Deruxtecan Applications Validated in EU for Patients with NSCLC
BUSINESSWIRE
04 Mar 2024
Share Share
Daiichi Sankyo spends €1B to bulk up in ADCs

Daiichi Sankyo spends €1B to bulk up in ADCs
FIERCE PHARMA
20 Feb 2024
Share Share
Dato-DXd BLA accepted in the US for patients with advanced nonsquamous NSCLC

Dato-DXd BLA accepted in the US for patients with advanced nonsquamous NSCLC
BUSINESSWIRE
19 Feb 2024
Share Share
Daiichi invests 1 bln eur near Munich to make precision cancer drugs

Daiichi invests 1 bln eur near Munich to make precision cancer drugs
PRESS RELEASE
17 Feb 2024
Share Share